Maxime Dely: How Long Can Europe Rely on U.S. Plasma
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”The core issue is clear: American Dependence: How long can Europe rely on U.S. Plasma?
In 2024, nearly 70 % of the world’s plasma used to produce plasma-derived medicinal products came from the United States. A figure that clearly shows how vulnerable Europe remains in a domain essential to patient care.
The U.S. collects around 50 million liters of plasma each year, enabled by a highly industrialized model, a dense network of donation centers, and financial compensation for donors.
By contrast, Europe collects only about 9 million liters, mostly concentrated in Austria, Germany, Hungary, and the Czech Republic. The rest of the continent remains largely dependent on imports.
Since 2023, global demand has been rising quickly (+ 12 to + 14%), driven by increased needs for immunoglobulins. But European collection is growing too slowly to close the gap.
To strengthen supply security, Europe has launched several initiatives:
▪️ EU4Health and resilience programs,
▪️ Investments to modernize collection infrastructures,
▪️ Efforts to increase voluntary non-remunerated donations,
▪️ Expansion of local fractionation capacity.
These initiatives represent real progress, but they come after years of structural dependence. Achieving European plasma sovereignty will require coordinated, long-term, and ambitious action.
The core issue is clear: ensuring continuous and secure access to plasma-derived medicines for all European patients.
In your review, what should be the top priority to rebalance this dependency?
Boosting collection? Rethinking the model? Investing in local production?”
Stay updated with Hemostasis Today.
-
Apr 16, 2026, 18:27Are We Underestimating VTE After PanNET Surgery? – RPTH Journal
-
Apr 16, 2026, 16:10Hamid Noori: Etiological Classification of Anemia Understanding the Root Cause
-
Apr 16, 2026, 15:29Sebastian Klapa: Key Findings On Mortality And Cardiovascular Risk In ANCA-Associated Vasculitis
-
Apr 16, 2026, 15:23Ifeanyichukwu Ifechidere: Argatroban – Its ‘Rescue Mission’ in Heparin-Induced Thrombocytopenia
-
Apr 16, 2026, 14:58Early Diagnosis Can Change Everything in Hemophilia Care – WFH
-
Apr 16, 2026, 14:05Saleh Shamse Basha: When Platelet Counts Mislead, The PLT-F Becomes Critical
-
Apr 16, 2026, 13:44Maha Othman: Celebrating National Medical Laboratory Week in Canada
-
Apr 16, 2026, 13:42Megan Adediran: How Much of What You Know About Hemophilia Is True?
-
Apr 16, 2026, 13:35Priya Singh: How to Write the Discussion of a Research Paper